CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,097 enrolled
Drug / intervention
Descemet membrane endothelial keratoplastyprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05134480
NCT05134480N/ACompleted
CompareCT.gov

Diabetes Endothelial Keratoplasty Study (DEKS): Impact of Diabetes on Corneal Transplant Success and Endothelial Cell Loss

Case Western Reserve University·interventional·Posted Nov 26, 2021·Updated Apr 16, 2026

In Brief

A clinical study evaluating Descemet membrane endothelial keratoplasty for Corneal Endothelial Decompensation and Fuchs' Endothelial Dystrophy. Completed, enrolled 1,097 participants across 2 sites.

Detailed Summary

This double-masked multi-center trial will evaluate the association of diabetes in the cornea donor with transplant success and loss of endothelial cells through 1 year following Descemet membrane endothelial keratoplasty (DMEK). Study eyes are assigned to receive either a cornea from a donor without diabetes or a cornea from a donor with diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorneal Endothelial Decompensation, Fuchs' Endothelial Dystrophy
CountriesUnited States
CollaboratorsJaeb Center for Health Research, National Eye Institute (NEI)

Timeline

N/ACompletedFinished
20222023202420252026
First PostedNov 26, 2021
Enrollment StartJan 21, 2022
Primary CompletionJul 15, 2025
Study CompletionSep 15, 2025
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 4.6 years ago

Interventions

Descemet membrane endothelial keratoplastyprocedure

cornea transplant procedure to replace dysfunctional endothelial cell layer